Criteria Bio Ventures

Tolerance Bio is a biopharmaceutical company dedicated to extending healthspan by restoring and preserving the function of the thymus, a critical organ for immune system regulation. The company's innovative approach involves creating artificial, bio-engineered thymus tissue using induced pluripotent stem cells (iPSCs), which can then be used to establish and maintain immune tolerance in patients, potentially treating a wide range of immune-mediated diseases.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

AbolerIS Pharma is a biotechnology company based in Nantes, France, specializing in the development of immune-modulators aimed at treating transplant rejection, graft-versus-host disease, and autoimmune diseases. Incorporated in 2019, the company offers innovative products such as Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma employs a unique therapeutic approach that fosters immune tolerance while preserving beneficial immune responses in the context of inflammatory, autoimmune, and degenerative diseases. This strategy allows the company to focus on advancing novel drugs to address significant unmet medical needs in these therapeutic areas.